GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Inventory Turnover

BeiGene (HKSE:06160) Inventory Turnover : 0.29 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BeiGene Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. BeiGene's Cost of Goods Sold for the three months ended in Mar. 2024 was HK$977 Mil. BeiGene's Average Total Inventories for the quarter that ended in Mar. 2024 was HK$3,375 Mil. BeiGene's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.29.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. BeiGene's Days Inventory for the three months ended in Mar. 2024 was 315.07.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BeiGene's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.57.


BeiGene Inventory Turnover Historical Data

The historical data trend for BeiGene's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Inventory Turnover Chart

BeiGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.18 1.20 1.00 1.09 1.09

BeiGene Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.31 0.30 0.29 0.29

BeiGene Inventory Turnover Calculation

BeiGene's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Inventory Turnover (A: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2023 ) / ((Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count )
=2967.099 / ((2198.177 + 3249.83) / 2 )
=2967.099 / 2724.0035
=1.09

BeiGene's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover (Q: Mar. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2024 ) / ((Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Mar. 2024 )) / count )
=977.367 / ((3249.83 + 3499.58) / 2 )
=977.367 / 3374.705
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BeiGene  (HKSE:06160) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BeiGene's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=3374.705/977.367*365 / 4
=315.07

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BeiGene's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=3374.705 / 5880.174
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


BeiGene Inventory Turnover Related Terms

Thank you for viewing the detailed overview of BeiGene's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene (HKSE:06160) Business Description

Traded in Other Exchanges
Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Executives
Jpmorgan Chase & Co. 2502 Approved lending agent
Oyler John Victor 2101 Beneficial owner
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Baker Felix James 2201 Interest of corporation controlled by you
Baker Julian Charles 2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc 2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p. 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Amgen Inc. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene (HKSE:06160) Headlines

No Headlines